Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 17/20 | 0.63 |
| ▸ | NSD2 | O96028 | 6/20 | 0.63 |
| ▸ | SPIN1 | Q9Y657 | 4/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.61 |
| ▸ | CHD1 | O14646 | 2/20 | 0.60 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351015 | 0.98 | EHMT2 (0.63) | EHMT2NSD2SPIN1DNMT1CHD1 | |
| SCHEMBL20336838 | 0.97 | EHMT2 (0.62) | EHMT2NSD2SPIN1DNMT1CHD1 | |
| SCHEMBL20351005 | 0.97 | EHMT2 (0.62) | EHMT2NSD2SPIN1DNMT1CHD1 | |
| SCHEMBL30509169 | 0.96 | EHMT2 (0.62) | EHMT2NSD2SPIN1DNMT1CHD1 | |
| SCHEMBL20336806 | 0.96 | EHMT2 (0.62) | EHMT2NSD2SPIN1DNMT1CHD1 | |
| SCHEMBL20347624 | 0.95 | EHMT2 (0.58) | EHMT2NSD2SPIN1DNMT1CHD1 | |
| SCHEMBL20351095 | 0.95 | EHMT2 (0.70) | EHMT2NSD2DNMT1 | |
| SCHEMBL23227155 | 0.94 | SPIN1 (0.59) | EHMT2NSD2SPIN1DNMT1CHD1 | |
| SCHEMBL22639562 | 0.94 | EHMT2 (0.70) | EHMT2NSD2DNMT1 | |
| Formic Acid SCHEMBL29387547 | 0.93 | EHMT2 (0.58) | EHMT2NSD2SPIN1DNMT1EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10829452-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EHMT2 2/4885NSD2 145/4885SPIN1 323/4885 |
| US-10829452-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EHMT2 3/4885NSD2 205/4885SPIN1 578/4885 |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EHMT2 2/4885NSD2 145/4885SPIN1 323/4885 |
| US-11713299-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EHMT2 3/4885NSD2 190/4885SPIN1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.